Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials.

Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials. Abstract Text:

Jooyun Lee,Gary P Wormser,

The purpose of this study was to begin to characterise the pharmacodynamic parameters of single-dose doxycycline for the prevention of Lyme disease following a tick bite. Based on limited data from published human and murine studies, it was found that there is a direct correlation between efficacy rate and the area under the time-concentration of free antibiotic curve divided by the minimum inhibitory concentration (fAUC/MIC) (R(2)=0.74, using Pearson correlation), but not the maximum concentration of free drug in serum divided by the MIC (fC(max)/MIC) or the time that the free drug concentration remains above the MIC (fT>MIC). To determine the possible implications of these findings for other antimicrobials, it was assumed that the pharmacodynamic properties of doxycycline would be pertinent to azithromycin, an antibiotic whose activity is known to correlate with AUC/MIC. By making such an extrapolation and using pharmacokinetic modelling with conservative assumptions on MIC values against Borrelia burgdorferi, it is hypothesised that a single 500mg dose of azithromycin in humans should have comparable efficacy to doxycycline for the prevention of Lyme disease. Additional experimental studies are needed to clarify more precisely the pharmacodynamic properties of doxycycline and to validate the accuracy of this hypothesis.

Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials. Publishing Authors By Initials

J Lee,GP Wormser,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: International journal of antimicrobial agents

VOLUME: 31

Page Numbers: 235-9

Journal Abbreviation: Int. J. Antimicrob. Agents

ISSN: 0924-8579

DAY: 15

MONTH: 01

YEAR: 2008

Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9111860

Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials.

AFFILIATION: Division of Infectious Diseases, Department of Medicine, New York Medical College, Valhalla, NY 10595, USA.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int J Antimicrob Agents

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials Related Publications

• From topical antidote against skin irritants to a novel counter-irritating and anti-inflammatory peptide.
• Hepatitis in association with rickettsialpox.
• Ocular Lyme disease: case report and review of the literature.
• Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials.
• Practice parameter: treatment of nervous system lyme disease (an evidence-based review): report of the quality standards subcommittee of the american academy of neurology.
• Protection from toxicants.
• Reinfection in patients with Lyme disease.
• [Not Available.]